Ocular acyclovir delivery by collagen discs: A mouse model to screen anti-viral agents

Willey, Dru E.; Williams, Iris; Faucett, Cheryl; Openshaw, Harry

doi:10.3109/02713689109020374

Cited by 5 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ciclopirox olamine at 3 μg/eye/dose was selected as a non-toxic maximal dose and a lower dose of 1 μg/eye/dose was also used to assess dose-responsiveness. ACV at 4.5 μg/eye/dose was used as a positive control because it was previously demonstrated to be effective in reducing HSV-1 replication in the cornea (Willey et al, 1991). A 3-fold lower dose of 1.5 μg/eye was also used.…”

Section: Resultsmentioning

confidence: 99%

Antifungal drug ciclopirox olamine reduces HSV-1 replication and disease in mice

Bernier

Morrison

2018

Antiviral Research

View full text Add to dashboard Cite

Herpes simplex virus (HSV)-1 and HSV-2 cause painful blisters and shallow ulcers in exposed skin and mucosae during primary or recurrent infection. In addition, recurrent and potentially blinding HSV-1 infections of the eye afflict nearly half a million persons in the U.S. Current clinical therapies rely on nucleoside analog drugs such as acyclovir (ACV) or ganciclovir to ameliorate primary infections and reduce the frequency and duration of reactivations. However, these treatments do not fully suppress viral shedding and drug-resistant mutants develop in the eye and in vulnerable, immunosuppressed patients. Herpesvirus DNA replication requires several enzymes in the nucleotidyl transferase superfamily (NTS) that have recombinase and nuclease activities. We previously found that compounds which block NTS enzymes efficiently inhibit replication of HSV-1 and HSV-2 by up to 1 million-fold in Vero and human foreskin fibroblasts. Among the compounds with potent suppressive effects in culture is the anti-fungal drug ciclopirox. Here we report that topical application of ciclopirox olamine to the eyes of mice infected with HSV-1 reduced virus shed from the corneal epithelium compared with saline control, and reduced development of blepharitis to the level of mice treated with ACV. Results were dose-dependent. In addition, treatment with ciclopirox olamine significantly reduced acute and latent HSV-1 infection of the peripheral nervous system. These results support further development of ciclopirox olamine as a repurposed topical agent for HSV infections.

show abstract

Section: Resultsmentioning

confidence: 99%